Galderma Group (OTCPK:GALD.Y) - Stock Price, News & Analysis

GALD.Y Stock Overview

Operates as a dermatology company worldwide. More details

GALD.Y fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	4/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 47.5% below our estimate of its fair value

Earnings are forecast to grow 44.43% per year

Revenue grew by 8.8% over the past year

Risk Analysis

No risks detected for GALD.Y from our risk checks.

Galderma Group AG Competitors

Teva Pharmaceutical Industries

NYSE:TEVA

US$18.8b

Viatris

NasdaqGS:VTRS

US$15.8b

Royalty Pharma

NasdaqGS:RPRX

US$15.7b

Catalent

NYSE:CTLT

US$11.1b

Price History & Performance

Summary of all time highs, changes and price drops for Galderma Group
Historical stock prices
Current Share Price	CHF 19.50
52 Week High	CHF 20.30
52 Week Low	CHF 15.51
Beta	0
11 Month Change	-1.81%
3 Month Change	1.14%
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	18.98%

Recent updates

Shareholder Returns

	GALD.Y	US Pharmaceuticals	US Market
7D	-1.5%	2.6%	0.5%
1Y	n/a	13.1%	30.7%

Return vs Industry: Insufficient data to determine how GALD.Y performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how GALD.Y performed against the US Market.

Price Volatility

Is GALD.Y's price volatile compared to industry and market?
GALD.Y volatility
GALD.Y Average Weekly Movement	5.7%
Pharmaceuticals Industry Average Movement	9.9%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.3%
10% least volatile stocks in US Market	3.1%

Stable Share Price: GALD.Y has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine GALD.Y's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1981	6,545	Flemming Ornskov	www.galderma.com

Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services that span the spectrum of the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Dysport/Azzalure, Alluzience, Restylane, and Sculptra in injectable aesthetics; Cetaphil and Alastin in dermatological skincare; and Soolantra, Epiduo, Differin, Aklief, Epsolay, Twyneo, Oracea, Metvix, Benzac, and Loceryl in therapeutic dermatology.

Galderma Group AG Fundamentals Summary

How do Galderma Group's earnings and revenue compare to its market cap?
GALD.Y fundamental statistics
Market cap	US$24.15b
Earnings (TTM)	-US$14.20m
Revenue (TTM)	US$4.32b

5.6x

P/S Ratio

-1,700x

P/E Ratio

Is GALD.Y overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GALD.Y income statement (TTM)
Revenue	US$4.32b
Cost of Revenue	US$1.31b
Gross Profit	US$3.00b
Other Expenses	US$3.02b
Earnings	-US$14.20m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Mar 06, 2025

Earnings per share (EPS)	-0.06
Gross Margin	69.54%
Net Profit Margin	-0.33%
Debt/Equity Ratio	37.1%

How did GALD.Y perform over the long term?

See historical performance and comparison

Galderma Group OTCPK:GALD.Y Stock Report